You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

VALEANT PHARMS INTL Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for VALEANT PHARMS INTL

VALEANT PHARMS INTL has three approved drugs.

There are six US patents protecting VALEANT PHARMS INTL drugs.

There are forty-four patent family members on VALEANT PHARMS INTL drugs in twelve countries.

Summary for VALEANT PHARMS INTL
International Patents:44
US Patents:6
Tradenames:3
Ingredients:2
NDAs:3

Drugs and US Patents for VALEANT PHARMS INTL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 DISCN Yes No 9,192,616 ⤷  Try for Free ⤷  Try for Free
Valeant Pharms Intl COLAZAL balsalazide disodium CAPSULE;ORAL 020610-001 Jul 18, 2000 AB RX Yes Yes 7,452,872*PED ⤷  Try for Free Y ⤷  Try for Free
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 DISCN Yes No 7,452,872 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VALEANT PHARMS INTL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Intl COLAZAL balsalazide disodium CAPSULE;ORAL 020610-001 Jul 18, 2000 4,412,992*PED ⤷  Try for Free
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 6,197,341 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VALEANT PHARMS INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1.1 g ➤ Subscribe 2013-11-05
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

VALEANT PHARMS INTL Market Analysis and Financial Projection

Valeant Pharmaceuticals International: A Comprehensive Market Analysis

Valeant Pharmaceuticals International, now known as Bausch Health Companies Inc., has been a significant player in the pharmaceutical industry. This analysis delves into the company's market position, strengths, and strategic insights, providing a comprehensive overview of its competitive landscape.

Company Overview

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic, and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices[1]. The company's portfolio spans various therapeutic areas, including dermatology, gastrointestinal disorders, eye health, and neurology.

Key Business Segments

Valeant's diverse product portfolio is divided into several key segments:

  1. Global Vision Care
  2. Global Surgical
  3. Global Consumer
  4. Global Ophthalmology Rx
  5. International
  6. Salix
  7. Dermatology
  8. Canada
  9. Dentistry
  10. Women's Health
  11. Neuro and Other
  12. Generics[1]

This diversification strategy has allowed Valeant to maintain a strong presence across multiple therapeutic areas and geographic regions.

Market Position and Competitive Advantage

Valeant has established itself as a leading player in several niche markets, particularly in dermatology and eye health. The company's acquisition of Bausch & Lomb in 2013 significantly strengthened its position in the ophthalmology sector[5].

Strengths and Competitive Edge

  1. Broad Product Base: Valeant boasts a portfolio of over 900 products, providing a diverse revenue stream[2].
  2. Global Presence: The company's products are marketed in more than 100 countries, reducing dependence on any single market[1].
  3. Strong Brand Recognition: Ownership of well-known brands like Bausch & Lomb enhances market penetration and customer loyalty[5].
  4. Acquisition Strategy: Valeant's growth has been largely driven by strategic acquisitions, allowing rapid expansion into new markets and therapeutic areas[6].
"Valeant's strategy is to focus on the business of core geographies and therapeutic classes, manage pipeline assets through strategic partnerships with other pharmaceutical companies and deploy cash with an appropriate mix of selective acquisitions, share buybacks and debt repurchases."[7]

Business Model and Strategy

Valeant's business model has been characterized by aggressive acquisition strategies and cost-cutting measures. This approach, while initially successful, has also been a source of controversy and scrutiny.

Acquisition-Driven Growth

Under the leadership of former CEO Michael Pearson, Valeant adopted a strategy of acquiring smaller pharmaceutical companies with effective medications and subsequently increasing the prices of those drugs[5]. This approach led to rapid growth, making Valeant the most valuable company in Canada in 2015[5].

Cost-Cutting Measures

Valeant's strategy involved significant cost-cutting post-acquisition, particularly in research and development (R&D). This approach differed markedly from traditional pharmaceutical companies that invest heavily in R&D[3].

Shift in Strategy

Following public scrutiny and regulatory investigations, Valeant has been working to distance itself from its previous controversial practices. In 2018, the company changed its name to Bausch Health Companies Inc., signaling a shift in strategy and corporate identity[5].

Financial Performance and Market Share

Valeant's financial performance has been volatile, reflecting both its rapid growth phase and subsequent challenges.

Historical Performance

From 2010 to 2015, Valeant was one of America's best-performing stocks, with its share price rising dramatically[6]. However, this period of growth was followed by a significant downturn.

Recent Challenges

Following investigations into its business practices, Valeant's stock price plummeted more than 90 percent from its peak, while its debt surpassed $30 billion[5]. This financial setback has necessitated a strategic overhaul and efforts to reduce debt.

Competitive Landscape

Valeant operates in a highly competitive pharmaceutical market, facing competition from both large multinational corporations and smaller specialty pharma companies.

Key Competitors

  1. Galderma
  2. Allergan
  3. Other specialty pharmaceutical companies[4]

Competitive Dynamics

The pharmaceutical industry is characterized by intense competition in research and development, pricing, and market access. Valeant's reduced focus on R&D sets it apart from many of its competitors, potentially impacting its long-term innovation pipeline.

Regulatory Environment and Challenges

Valeant has faced significant regulatory scrutiny, particularly regarding its pricing practices and financial reporting.

Investigations and Controversies

In 2015, Valeant was involved in controversies surrounding drug price hikes and the use of specialty pharmacies for distribution. This led to investigations by the U.S. Securities and Exchange Commission[5].

Impact on Business Operations

These regulatory challenges have necessitated changes in Valeant's business practices and have significantly impacted its market valuation and reputation.

Future Outlook and Strategic Direction

As Bausch Health Companies Inc., the company is working to rebuild its reputation and stabilize its financial position.

Debt Reduction Efforts

The company has committed to paying down significant portions of its debt, using proceeds from divestitures and cash flows from operations[1].

Refocusing on Core Strengths

Bausch Health is focusing on its core areas of strength, particularly in eye health and dermatology, while also investing in R&D to build a sustainable pipeline of new products.

Key Takeaways

  1. Valeant Pharmaceuticals, now Bausch Health, has a diverse portfolio spanning multiple therapeutic areas and geographies.
  2. The company's growth was primarily driven by an aggressive acquisition strategy and cost-cutting measures.
  3. Regulatory scrutiny and controversies led to significant financial and reputational challenges.
  4. The company is now focusing on debt reduction, rebuilding its reputation, and investing in core areas of strength.
  5. The future success of Bausch Health will depend on its ability to balance financial stability with innovation and market competitiveness.

FAQs

  1. Q: What led to Valeant Pharmaceuticals changing its name to Bausch Health? A: The name change in 2018 was part of an effort to distance the company from past controversies and signal a new strategic direction.

  2. Q: How does Bausch Health's R&D strategy differ from traditional pharmaceutical companies? A: Historically, Valeant focused less on internal R&D and more on acquiring companies with existing successful products. However, the company is now working to balance this approach with increased R&D investment.

  3. Q: What are the main therapeutic areas Bausch Health focuses on? A: The company's main focus areas include eye health, dermatology, gastrointestinal disorders, and neurology.

  4. Q: How has Bausch Health addressed its debt issues? A: The company has committed to paying down significant debt using proceeds from divestitures and cash flows from operations.

  5. Q: What is the current market position of Bausch Health in the pharmaceutical industry? A: While facing challenges, Bausch Health remains a significant player in several niche markets, particularly in eye health and dermatology.

Sources cited: [1] https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/2016-vrx-annual-report.pdf [2] https://www.mbaskool.com/swot-analysis/pharmaceuticals-and-healthcare/3315-valeant-pharmaceuticals.html [3] https://phrma.org/en/Blog/what-makes-valeant-different-than-innovative-biopharmaceutical-companies [5] https://en.wikipedia.org/wiki/Bausch_Health [6] https://live.transparently.ai/blog/the-valeant-scandal [7] https://www.bauschhealth.com/siteassets/PDF/Valeant_5415.pdf?ver=2021-05-21-022844-003

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.